Organ Donor Tissue Oxygen Saturation as a Predictor of Number of Organs to Transplant Per Donor

Sponsor
The Cleveland Clinic (Other)
Overall Status
Completed
CT.gov ID
NCT01819116
Collaborator
(none)
60
1
11
5.5

Study Details

Study Description

Brief Summary

The objective of this study is to quantify the association between tissue oxygen saturation (StO2) during the donor management phase of the Death by Neurological Criteria (DNC) organ donor and the number of organs transplanted per donor.

Condition or Disease Intervention/Treatment Phase

    Detailed Description

    Specifically the study aims to:
    1. Evaluate the association between StO2 level in the DNC organ donor and the number of organs transplanted per donor;

    2. Evaluate whether or not tissue perfusion in the DNC organ donor population correlates with currently measured macro-hemodynamic variables during the donor management phase.

    3. Assess if StO2 in the DNC organ donor is related to the number of organs with normal end-organ function, and with the number of organs predicted to be transplanted using the organ donor calculator.

    4. Assess if StO2 in the DNC organ donor is related with intravenous thyroid hormone treatment.

    Investigators will conduct an observational study, including 60 DNC organ donors, in Lifebanc's Donor Service Area (DSA). Investigators will monitor and record blindly the StO2 with near-infrared spectroscopy (NIRS) in the DNC organ donor from the beginning of the OPO (Organ Procurement Organization) organ donor management period until cardiac arrest in the operating room at the time of recovery.

    Study Design

    Study Type:
    Observational
    Actual Enrollment :
    60 participants
    Observational Model:
    Cohort
    Time Perspective:
    Prospective
    Official Title:
    Tissue Oxygen Saturation During Management of the Deceased by Neurological Criteria Organ Donor as a Predictor of Number of Organs to Transplant Per Donor
    Study Start Date :
    Apr 1, 2013
    Actual Primary Completion Date :
    Mar 1, 2014
    Actual Study Completion Date :
    Mar 1, 2014

    Outcome Measures

    Primary Outcome Measures

    1. Number of organs transplanted per donor [At 24 hours after transfering the donor to operating room.]

    Secondary Outcome Measures

    1. Number of organs with targeted end-organ function per donor [At the last hour at the Intensive Care Unit, before the donor is transferred to the operating room.]

      Normal end-organ function definitions Kidney function: Creatinine ≤ 1.5 mg/dL, urinary output ≥ 0.5 ml/kg/h Liver function: INR <1.5, Prothrombin time: 8.4-13 seconds (or within normal range per testing lab). Bilirubin, AST, ALT within normal range per laboratory limits. Lung function: PaO2/FiO2 index ≥ 300 with PEEP ≤ 8 (oxygen challenge gas) Heart function: Normal systolic and diastolic function per echocardiogram with minimal inotropic/vasopressor support. Systolic function will be estimated by ejection fraction and/or shortening fraction on echocardiogram. Normal cardiac catheterization data if available Pancreatic function: HbA1c<6, amylase and lipase within normal range per laboratory limits. Small intestine function: lactate ≤ 2.2 mmol/L with minimal vasopressor support.

    2. Number of organs predicted to be transplanted using organ donor calculator [At the last hour at the Intensive Care Unit, before the donor is transferred to the operating room.]

    3. Correlation of tissue oxygenation readings to macro-hemodynamic measurements [During donor management until cardiac arrest at the operating room]

      Mean arterial pressure, central venous pressure, cardiac output, positive pressure variation, stroke volume variation

    4. Variation of tissue oxygenation after thyroid hormone is initiated, titrated and/or discontinued. [During donor management until cardiac arrest at the operating room]

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    15 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. DNC organ donor

    2. Age ≥ 15 years old

    3. Weight ≥ 45 Kg

    Exclusion Criteria:
    1. Donor after circulatory determination of death

    2. Living donor

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Cleveland Clinic Cleveland Ohio United States 44195

    Sponsors and Collaborators

    • The Cleveland Clinic

    Investigators

    • Principal Investigator: Silvia Perez-Protto, MD, The Cleveland Clinic
    • Study Director: Daniel Lebovitz, MD, Akron Children Hospital - Lifebanc
    • Study Director: J. Steven Hata, MD, The Cleveland Clinic

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Silvia Perez-Protto, MD, M.D., The Cleveland Clinic
    ClinicalTrials.gov Identifier:
    NCT01819116
    Other Study ID Numbers:
    • 13-020
    First Posted:
    Mar 27, 2013
    Last Update Posted:
    Jan 27, 2016
    Last Verified:
    Mar 1, 2014
    Keywords provided by Silvia Perez-Protto, MD, M.D., The Cleveland Clinic
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Jan 27, 2016